Ποια είναι η τιμή για Incannex Healthcare Limited (IHL)

Η τιμή για Incannex Healthcare Limited (IHL) είναι $0.0270762

Ποια είναι η κεφαλαιοποίηση αγοράς για Incannex Healthcare Limited (IHL)

Η κεφαλαιοποίηση αγοράς για Incannex Healthcare Limited (IHL) είναι $6.78M

Incannex Healthcare Limited (IHL) Τιμή και Κεφαλαιοποίηση Αγοράς

Established in Melbourne, Australia, in 2001, Incannex Healthcare Limited, which operated as Impression Healthcare Limited until its rebranding in June 2020, is dedicated to the research, development, and commercialization of pharmaceutical products and therapies derived from medicinal cannabinoids and psychedelics. Its offerings include a trio of ultrapure cannabinoid compounds: APIRx-1801 (tetrahydrocannabinol), APIRx-1802 (CBD), and APIRx-1803 (cannabigerol). The company's clinical pipeline features IHL-42X, which has concluded Phase IIa trials for obstructive sleep apnea, and Psi-GAD, currently in Phase IIa development for generalized anxiety disorder. Other compounds having successfully advanced through Phase IIa clinical trials include CanChew Plus for irritable bowel syndrome, APIRx-1601 for vitiligo, APIRx-1602 for psoriasis, and APIRx-1603 for atopic dermatitis. Additionally, MedChew Dronabinol has completed Phase Ia trials for chemotherapy-induced nausea and vomiting. Its pre-clinical portfolio is extensive, including IHL-675A, which has completed studies for inflammatory lung disease, rheumatoid arthritis, and inflammatory bowel disease, alongside IHL-216A for traumatic brain injury/concussion. A broad array of further candidates are actively undergoing pre-clinical investigation, such as MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpetic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for Crohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for cannabis addiction, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, and APIRx-1702 for dry eye syndrome.

Η τιμή για IHL	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$21,786.35 $6.78M	NVDA	$5.452T	+80,462,990.67%
$17,942.68 $6.78M	AAPL	$4.490T	+66,267,263.35%
$16,633.50 $6.78M	GOOG	$4.162T	+61,432,082.46%
$14,691.13 $6.78M	MSFT	$3.676T	+54,258,346.74%
$11,321.19 $6.78M	AMZN	$2.833T	+41,812,243.37%

Η τιμή για IHL

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$21,786.35 $6.78M